Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives [PDF]
Artur Dziewierz,1 Tomasz Rakowski,1 Dariusz Dudek2 12nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland; 2Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland Abstract ...
Dziewierz A, Rakowski T, Dudek D
doaj +2 more sources
Abciximab: a reappraisal of its use in coronary care
Marco Valgimigli, Gianluca Campo, Matteo Tebaldi, Roberto Carletti, Chiara Arcozzi, Roberto Ferrari, Gianfranco PercocoCardiovascular Institute, Azienda Ospedaliera Universitaria S.
Marco Valgimigli +5 more
doaj +1 more source
Comparative efficacy of eptifibatide and abciximab in primary angioplasty study [PDF]
Rohan Jayasinghe1 Matias Yudi1 Sanjay Jayasinghe21Cardiology Department, Gold Coast Hospital, Griffith University, Queensland, Australia; 2Centre for Immunisation Research, Sydney, AustraliaBackground: Primary percutaneous intervention is the safest and ...
Rohan Jayasinghe +2 more
doaj +3 more sources
Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
Jennifer Vergara-Jimenez, Pierluigi TricociDepartment of Medicine-Cardiology, Duke Clinical Research Institute, Durham, North Carolina, USAAbstract: Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients ...
Jennifer Vergara-Jimenez +1 more
doaj +1 more source
Retention of critical platelet hemostatic functions of amotosalen-UVA pathogen-reduced cryoprecipitated fibrinogen complex. [PDF]
Abstract Background Cryoprecipitate Anti‐Haemophilic Factor (CRYO‐AHF) is enriched for fibrinogen, VWF, FVIII, FXIII and fibronectin, but has short post‐thaw expiration due to risk of transfusion‐transmitted infection (TTI) limiting availability for rapid treatment.
Tupin F +6 more
europepmc +2 more sources
Pathogen-reduced plasma, cryoprecipitate reduced for therapeutic plasma exchange. [PDF]
Abstract Background Therapeutic plasma exchange (TPE) for thrombotic thrombocytopenic purpura (TTP) and auto‐immune disorders involves repeated patient exposure to allogenic plasma with the risk of transfusion‐transmitted infection (TTI).
Tupin F +6 more
europepmc +2 more sources
Optimising coronary reperfusion in acute myocardial infarction: the role of primary angioplasty [PDF]
PhDThrombolysis remains the predominant reperfusion strategy for ST segment elevation myocardial infarction (STEMI) in the United Kingdom. Although primary angioplasty may offer superior outcomes, the logistics of delivering this therapy in the UK ...
Smith, Elliot J
core +4 more sources
Breaking the Barrier: Unraveling the No-Reflow Phenomenon in Cardiovascular Medicine. [PDF]
ABSTRACT The no‐reflow phenomenon is a stubborn and often devastating complication in cardiovascular medicine, where blood flow is restored to an artery, yet the microvasculature remains unresponsive. First identified in 1967, this phenomenon has haunted clinicians and researchers alike, particularly in the context of acute myocardial infarction (AMI).
Howes S +9 more
europepmc +2 more sources
Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy. [PDF]
Current integrin αIIbβ3 inhibitors effectively reduce thrombosis but also increase bleeding risk. During thrombosis, high shear blood flow can directly activate the integrin αIIbβ3 via a distinct topological change in the β3 transmembrane domain, independent of hemostatic platelet signaling.
Lee J +11 more
europepmc +2 more sources
Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper. [PDF]
ABSTRACT Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDs are aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs).
Cortellini G +10 more
europepmc +2 more sources

